Compare DexCom, Inc. (DXCM) vs Ferrari NV (RACE) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Ferrari (RACE) trades at $381.51, up 3.35% today, with a bullish technical signal from moving averages and strong fundamentals including 22.19% net income margin and 41.96% ROE. Recent earnings beats and a $3.62 dividend highlight operational strength, while a multi-year share buyback program and upcoming Q2 2026 results on July 30, 2026 (GlobeNewsWire, 2026-07-15) provide near-term catalysts.

The outlook remains positive given analyst consensus price target of $467.50 (72.22% buy ratings), though high valuation multiples (P/E 36.7) and EV transition risks pose challenges. Stock investors may find opportunity in Ferrari's pricing power and margin resilience, balanced against macroeconomic sensitivity and execution risks on new models.